Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab for macular edema secondary to CRVO (CRUISE)
NCT00485836Phase 3Completed
- Sponsor
- Genentech
- Start
- Jul 2007
- Primary completion
- Jun 2009
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 3 trial of ranibizumab in macular edema, sponsored by Genentech. Started Jul 2007; status: completed.
02
Drugs
ranibizumab
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT00485836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00485836.